Cambrian Biopharma, LG, GlaxoSmithKline, Novo and Takeda all invested in the cell therapy developer to help it close its series C round.

Arcellx, a US-based developer of cancer and autoimmune disease therapies, raised $115m yesterday in a series C round featuring medical research group Cambrian Biopharma, diversified conglomerate LG and pharmaceutical firms GlaxoSmithKline (GSK), Novo and Takeda.

Samsara BioCapital and CAM Capital co-led the round, which included Adage Capital, Asymmetry, CaaS Capital, Sixty Degree Capital, Soleus Capital, Surveyor Capital, Suvretta, Terra Magnum Capital Partners, New Enterprise Associates (NEA) and Clough Capital Partners.

GSK, LG and Takeda took part in the round through…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?